CD38 and Miyoshi myopathy: These advances include the FDA approval of the proteasome inhibitors bortezomib [48], carfilzomib [49] (and ixazomib for some patients) [50] as front-line therapies for MM, as well as the addition of anti-CD-38 antibody, daratumumab [51].